Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT01130506 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

NIH

Sponsor class

Conditions

Previously Treated Myelodysplastic Syndrome
Recurrent Adult Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Secondary Acute Myeloid Leukemia
Therapy-Related Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia

Interventions

DRUG: Cytarabine
DRUG: Decitabine
OTHER: Laboratory Biomarker Analysis
OTHER: Pharmacological Study
DRUG: Vorinostat

Sponsor

National Cancer Institute (NCI)